Standigm is a workflow AI-driven drug discovery company. Standigm has proprietary AI platforms encompassing novel target identification to lead generation to generate commercially valuable drug pipelines. Founded in 2015, the company has established an early-stage drug discovery workflow AI to generate First-in-Class lead compounds within seven months. Pursuing full-stack, AI-driven industrializing drug discovery, Standigm has achieved the automation of molecular design workflow through DarkMolFactory™, and the automation effort has been expanding to the whole drug discovery process on the basis of Standigm AI platforms, including Standigm ASK™ for target discovery, Standigm BEST™ for lead design, and Standigm Insight™ for drug repurposing. Learn more at http://www.standigm.com.
Looking for a particular Standigm employee's phone or email?
The Standigm annual revenue was $15.5 million in 2026.
Sang Song is the CEO of Standigm.
25 people are employed at Standigm.
Standigm is based in Gangnam-gu, Seoul.
The NAICS codes for Standigm are [5417, 54171, 54, 541715, 541].
The SIC codes for Standigm are [873, 87].